Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight rating on the shares following the company reporting a Q2 revenue beat and raising 2025 revenue guidance. Given the firm’s belief that MiMedx and Organogenesis (ORGO) are positioned to take market share in 2026 and represent undervalued opportunities, it would be buyers amid the share’s strength.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: